Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mary Jo Laffler

Mary Jo Laffler oversees US commercial content for Informa’s pharmaceutical news publications, working with a group of talented reporters and editors covering business, commercial and clinical news. She brings 16 years of experience reporting on the pharmaceutical industry for the Pink Sheet and affiliated publications, serving previously as Bureau Chief for Clinical Development and Business News, managing editor of the Pink Sheet and as one of the first managing editors for the Pink Sheet DAILY. While wearing many hats has given Mary Jo a wide-ranging knowledge of the commercial and regulatory challenges facing the pharmaceutical industry, her specialty is in analyzing drug development news and R&D strategy.
Advertisement
Set Alert for Articles By Mary Jo Laffler

Latest From Mary Jo Laffler

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math

Amgen walks through its price-setting model for PCSK9 inihibitor Repatha and says new outcomes data just presented at ACC provides more evidence that "prices that exist in the market are indeed value-based."

Health Technology Assessment Reimbursement

Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.

Reimbursement Market Access

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.

Clinical Trials Market Access

What To Look Out For At ACC

Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.

Cardiovascular Clinical Trials

Teva Undertaking Strategic Review As It Searches For New CEO

Execs were pushed for details during earnings call but offer minimal clarity. Teva is sticking by the guidance issued before its loss in Copaxone patent case, and is upping investment in promoting the brand while the decision is appealed.

Sales & Earnings Business Strategies

J&J Outlines Pricing Transparency Plan, Will Others Follow?

CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.

Pricing Debate Sales & Earnings
See All
Advertisement
UsernamePublicRestriction

Register